Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of GHK-Cu and SNAP-8 — mechanism, dosing, side effects, legal status, and pricing.
GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine, first identified in human plasma by Loren Pickart in 1973. Plasma GHK declines with age. It is best established as a topical cosmetic ingredient for photoaged skin; it is NOT an FDA-approved drug in any jurisdiction.
GHK-Cu
SNAP-8
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
GHK-Cu
SNAP-8
COA corpus from Disclosed Labs — independently tested batches only.
GHK-Cu
215
COAs
99.6%
Avg purity
17
Labs
SNAP-8
32
COAs
99.4%
Avg purity
7
Labs
GHK-Cu is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. SNAP-8 remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
GHK was identified in human plasma by Pickart in 1973 and characterized as a copper-binding tripeptide in Nature in 1980 (PMID 7453802). Controlled topical studies in photoaged human skin have shown improvements in skin appearance and density with ~2% formulations. Pickart's 2014 review 'GHK and DNA: resetting the human genome to health' (PMID 25302294) and 2018 Int J Mol Sci review 'Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data' (PMID 29986520) summarize transcriptomic data showing modulation of thousands of genes involved in tissue repair, DNA repair, antioxidant defense, and anti-inflammation. The SubQ protocols circulating in the peptide community (typically 1-2 mg) are not supported by controlled human trials.
Key references
In-vitro and small clinical-cosmetic studies on wrinkle depth reduction.
GHK-Cu and SNAP-8 are both in the Cosmetic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs